HomeProductsBioactive CompoundsApoptosisCaspasePralnacasan
Chemical structure of CAS 192755-52-5

Pralnacasan

In Stock•Starting at $1553 for 1 mg•Purity ≥ 98.75%
CAS No.192755-52-5
MDL No.MFCD18381953
MFC26H29N5O7
MW523.50
InChI KeyCXAGHAZMQSCAKJ-WAHHBDPQSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
1 mg98.75%$1553In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.192755-52-5
Product NamePralnacasan
Heavy Atom Count38Rotatable Bond Count6
Atom Stereo Count4Bond Stereo Count0
HBA8HBD2
TPSA147.240 ŲCharge0
Exact Mass523.20670Complexity1278.37
pKa5.875XLogP0.656

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat.

Neuropharmacology • Vol. 53, Issue 5 • 2007
PMID: 17845807DOI: 10.1016/j.neuropharm.2007.07.015

(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18.

The Journal of pharmacology and experimental therapeutics • Vol. 321, Issue 2 • 2007
PMID: 17289835DOI: 10.1124/jpet.106.111344

Caspase inhibitors: a pharmaceutical industry perspective.

Current topics in medicinal chemistry • Vol. 5, Issue 16 • 2005
PMID: 16375749DOI: 10.2174/156802605775009720

Documentation